Infectious Disease & Vaccines

ABL specialises in the development and manufacture of advanced biological therapeutics, with a particular focus on gene therapies, vaccines, oncolytics and immunotherapies . Working exclusively with client programmes rather than proprietary pipelines, the company positions itself as a dedicated development partner for organisations tackling some of the most complex disease areas in modern medicine. The company's manufacturing capabilities span virus manufacturing and process development, aseptic fill finish, and cell and virus banking. These services are supported by biologics and quality control testing, giving clients access to an integrated development pathway under a single provider. ABL also supplies ELISA kits as commercial products, reflecting a broader engagement with laboratory and analytical workflows. Government partnering is listed as a distinct service category, indicating that ABL works with public-sector and defence-adjacent clients in addition to commercial biotechnology and pharmaceutical sponsors. This positions the company within the wider landscape of biodefence and public health preparedness, alongside conventional clinical-stage biologics work. The organisation operates under the ABL, Inc. legal identity and maintains multiple locations, supporting projects across process development, manufacturing scale-up, and aseptic production. Its integrated service model is suited to sponsors requiring continuity across early development and late-stage manufacturing without transferring programmes between providers. Further information is available at ablinc.com.

Acino operates as a speciality pharmaceutical company with a deliberate focus on emerging and underserved markets, channelling its commercial and manufacturing capabilities into regions including Africa, Latin America, the Middle East, Turkiye, North Africa, Ukraine, and the broader Eurasian corridor. This geographic strategy positions the Swiss-headquartered group where established multinationals have historically had thinner reach. The company's operational model spans three integrated pillars: partnering arrangements with third-party rights holders, in-house manufacturing supported by dedicated manufacturing sites, and direct product marketing. Quality assurance and supplier governance are identified as components of the manufacturing framework, reflecting the compliance requirements that apply across international markets. Acino's therapeutic portfolio addresses conditions prevalent in the markets it serves. Disease areas covered include cardiovascular disease, hypertension, infectious diseases, acid reflux, Helicobacter pylori infection, colorectal cancer, and narcolepsy. The company also maintains patient-facing health information on these conditions, indicating a level of engagement beyond the purely commercial. Counterfeit medicines awareness is included among its health matter communications, a consideration of particular relevance in markets with complex distribution environments. Sustainability forms part of the company's published agenda, alongside career development and media engagement, suggesting an organisation structured for long-term presence in its chosen regions rather than opportunistic market entry. Further information is available at acino.swiss.

Rooted in decades of albumin science first pioneered at Delta Biotechnology and later advanced under Novozymes Biopharma, Albumedix is a Nottingham-based biotechnology company that produces recombinant human serum albumin for pharmaceutical and bioprocessing applications. The company emerged as an independent entity following Novozymes' divestment of its biopharma operations, carrying forward a well-established manufacturing and regulatory heritage. Its flagship material, Recombumin, is expressed in Saccharomyces cerevisiae yeast and is entirely free of animal-derived and plasma-derived components. This origin gives manufacturers a consistent, traceable alternative to plasma-sourced albumin, addressing both supply-chain risk and evolving regulatory expectations around animal-free raw materials in biopharmaceutical production. Applications Across Biologics Manufacturing Albumin-based excipients supplied by Albumedix are used as stabilisers in vaccines, cell and gene therapy products, and protein biologics, where formulation integrity directly affects product shelf life and clinical performance. Beyond final-product formulation, Recombumin is also incorporated into cell culture media and bioprocessing workflows, supporting the growth of sensitive mammalian cell lines used in biologics development. The company operates under pharmaceutical-grade quality systems, with its materials referenced in regulatory dossiers for licensed medicines across multiple markets. Albumedix works with global pharmaceutical manufacturers, contract development and manufacturing organisations, and advanced therapy developers seeking compliant, well-characterised albumin raw materials. Further information is available at albumedix.com.

Dedicated entirely to Phase II-IV clinical trials , Albuquerque Clinical Trials has operated as a locally owned, independent research centre since 1988. Based in Albuquerque, New Mexico, the site conducts studies on behalf of pharmaceutical and biotechnology sponsors across a broad range of therapeutic areas. The facility's in-house team brings together board-certified physicians, a PharmD, certified study coordinators, licensed clinicians, regulatory specialists, recruitment professionals and data entry personnel. This integrated staffing model allows the centre to manage all phases of a trial from a single site, reducing sponsor coordination burden and supporting consistent data quality. The active study portfolio covers a diverse set of indications, including type I and type II diabetes , obesity-related conditions, weight loss, gout, heart failure prevention, systemic lupus erythematosus, coeliac disease, migraines, male incontinence, constipation and infectious disease, including a C. difficile vaccine programme. Birth control and menstrual migraine studies are also listed among current or recent therapeutic areas, reflecting the breadth of the clinical programme. The centre states its core commitments as exceeding sponsor expectations for dependability, human protection, subject enrolment and overall performance, with the broader aim of improving patient health through access to innovative therapies. Patient-facing infrastructure includes a dedicated sign-up pathway and a sponsor referral channel. Further information is available at abqct.com.

Grounded in a proprietary boron chemistry platform , AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology , with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases , particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

Emergex Vaccines is a UK-based clinical-stage biotechnology company developing a new class of synthetic peptide vaccines designed to stimulate cytotoxic T-lymphocyte (CTL) responses rather than the antibody-driven immunity targeted by conventional vaccines. Founded in 2015 and headquartered in Abingdon, Oxfordshire, the company was established on the premise that T-cell immunity offers broader and more durable protection against rapidly mutating viral pathogens, including pandemic influenza strains and other emerging infectious threats. Platform Technology and Pipeline The company's core platform centres on short synthetic peptide constructs derived from conserved viral protein sequences. Because these sequences change little across viral variants, the approach aims to produce vaccines with cross-strain efficacy, addressing a central limitation of seasonal influenza vaccines that must be reformulated annually. Emergex has advanced candidates targeting influenza A and dengue fever through early-phase clinical evaluation, with additional programmes directed at other flaviviruses and respiratory viruses. Development and Funding Background Emergex has received support from UK public funding bodies and private investors to progress its pipeline from pre-clinical research into Phase I clinical trials. The company operates under a largely asset-light model, collaborating with contract research organisations and academic partners to conduct clinical work. As a private company, Emergex does not carry a public stock listing. Its programmes are positioned within the broader landscape of next-generation vaccine development , addressing unmet needs in both seasonal infectious disease management and pandemic preparedness. Further information is available at emergexvaccines.com.

Led by Liverpool School of Tropical Medicine and embedded within the North West of England, iiCON (Infection Innovation Consortium) is an open-innovation programme that brings together academic, industry and public-sector partners to accelerate the discovery and development of solutions to infectious disease. Partners include Unilever, LifeArc and Medicines for Malaria Venture, reflecting the consortium's reach across consumer health, life sciences investment and global disease control. The programme operates across eleven distinct research and development platforms , spanning the full pipeline from early-stage bioactive discovery to clinical evaluation. The Bioactives Library supports the identification of novel antimicrobial agents, while the Hits to Leads platform progresses promising compounds towards new antibiotic candidates. Organoid modelling and advanced AMR modelling platforms underpin mechanistic drug discovery and resistance research, and a dedicated Human Challenge platform enables small-scale clinical trials in a controlled setting. Diagnostic development sits at the heart of iiCON's translational work. Published case studies document progress on a sputum-free diagnostic for tuberculosis, a scalable test for avian influenza, and a rapid test for antimicrobial resistance, all developed through the consortium's open-innovation microbiome ecosystem model. Further platforms address randomised controlled trials, mapping and modelling, nanotherapeutics, antibody humanisation, and long-acting therapeutics, giving the consortium a broad capability base across the infectious disease space. A dedicated technology arm, iiTECH, extends this work into applied sensing and quality assurance, with demonstrated projects including lymphatic filariasis sensors and indoor residual spraying quality assurance tools deployed across Africa and India. Further information is available at infectioninnovation.com.

Founded by Paul Janssen in Beerse, Belgium in 1953 and now operating as the pharmaceutical division of Johnson Johnson, Janssen Global stands among the world's foremost research-driven pharmaceutical organisations. The business concentrates scientific and commercial resources on discovering, developing and delivering transformative medicines across oncology, immunology, infectious diseases and neuroscience, with a particularly strong record in haematological malignancies and autoimmune conditions. Therapeutic Focus and Pipeline Depth Janssen's approved portfolio illustrates the breadth of its therapeutic reach. In oncology and haematology , Darzalex (daratumumab) has become a standard-of-care option across multiple myeloma lines, while Imbruvica (ibrutinib), developed in collaboration with AbbVie, is approved across several B-cell malignancies. Zytiga (abiraterone acetate) remains a recognised treatment in metastatic prostate cancer. In immunology, Stelara (ustekinumab) and Tremfya (guselkumab) address moderate-to-severe plaque psoriasis and other inflammatory conditions. The neuroscience portfolio includes Spravato (esketamine), a nasal-spray formulation approved for treatment-resistant depression in adults. HIV and tuberculosis medicine reflects a long-standing infectious disease commitment carried through products such as Edurant (rilpivirine) and contribution to combination regimens used globally. Global Operations and Research Infrastructure Research and development hubs span Beerse, Spring House (Pennsylvania), La Jolla (California), Leiden in the Netherlands and Shanghai, supporting a pipeline that extends from early discovery through late-stage clinical programmes. Janssen works alongside academic medical centres, biotech partners and health systems to accelerate access. As a central component of Johnson Johnson's pharmaceutical segment, operating under the J J Innovative Medicine banner from 2023, the organisation benefits from the group's global manufacturing network, regulatory infrastructure and substantial annual R D investment. Its pharmaceutical pipeline spans both small molecules and large biologics, with active programmes in areas such as solid tumours, multiple sclerosis and pulmonary arterial hypertension. Further information is available at janssen.com.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is a clinical-stage biotechnology company listed on the Nasdaq (ticker: MRNA) that has built its entire operation around a single scientific bet: that messenger RNA can be harnessed as a programmable medicine. Rather than developing one drug at a time, the company operates as an mRNA platform business, using the same underlying technology to generate candidates across vaccines, oncology, rare disease and cardiovascular indications. The mRNA Platform and Pipeline More than fifteen years of continuous mRNA research underpin Moderna's proprietary mRNA Design Studio , a discovery and development environment that allows scientists to design, iterate and optimise mRNA sequences with a speed that conventional small-molecule or biologics programmes cannot match. The platform has already produced two approved products: Spikevax, its COVID-19 vaccine authorised in multiple markets worldwide, and mRESVIA, an mRNA-based vaccine for respiratory syncytial virus approved by the US FDA in 2024 for adults aged 60 and over. A broad pipeline sits behind these approvals, including an investigational seasonal influenza vaccine (mRNA-1010), a personalised cancer vaccine programme developed in collaboration with Merck that uses individualised mRNA sequences to target tumour-specific neoantigens, and candidates targeting cytomegalovirus, latent HIV and rare metabolic disorders. Global Operations and Commercial Scale Moderna maintains country-specific commercial and regulatory operations across North America, Europe and Asia Pacific, with established presences in the United States, Canada, the United Kingdom, France, Germany, Italy, the Netherlands, Spain, Switzerland, Poland, Australia, Japan, South Korea, Hong Kong, Taiwan and Singapore. The company has received substantial non-dilutive funding through longstanding partnerships with US government agencies including BARDA and DARPA, which supported its early platform work. Investor relations, healthcare professional resources, supplier programmes and a clinical trials portal are all maintained as distinct operational functions, consistent with Moderna's scale as a multi-market biopharmaceutical organisation. Further information is available at modernatx.com.

Novavax, Inc. is a Gaithersburg, Maryland-based vaccine biotechnology company founded in 1987 and listed on NASDAQ (ticker: NVAX), best known for developing protein subunit vaccines using its proprietary Matrix-M adjuvant platform. Unlike mRNA or viral-vector approaches, Novavax produces recombinant nanoparticle antigens that mimic the surface of a pathogen, pairing them with Matrix-M, a saponin-based formulation derived from the Quillaja saponaria tree, to generate robust immune responses with a well-characterised tolerability profile. NVX-CoV2373 and COVID-19 Programme Novavax received its first major regulatory milestones through its COVID-19 vaccine, NVX-CoV2373, marketed as Nuvaxovid. The vaccine secured Emergency Use Authorisation from the US FDA, conditional marketing authorisation from the European Medicines Agency, and approvals in numerous countries across Asia-Pacific, Europe, and the Americas. Nuvaxovid became a significant addition to global vaccination campaigns as a protein-based alternative for individuals who preferred a non-mRNA option, with the World Health Organization granting it Emergency Use Listing. Updated formulations targeting later SARS-CoV-2 variants have continued to advance through regulatory review. Pipeline and Strategic Partnerships Beyond COVID-19, Novavax applies its platform to influenza vaccines , with a quadrivalent recombinant candidate in late-stage development, and combination respiratory programmes including a COVID-influenza co-formulation. The company has historically held collaboration agreements with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, and has executed manufacturing and supply partnerships with organisations including Serum Institute of India to support large-scale global distribution. Novavax's corporate growth strategy centres on out-licensing the Matrix-M adjuvant to third-party vaccine developers, extending the platform's reach across a broad range of infectious-disease targets. The company publishes peer-reviewed scientific findings through a dedicated publications resource and maintains transparency with the research and investment communities through its public filings and investor relations programme. Further information is available at novavax.com.

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology , haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.